WO1992001801A1 - Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus - Google Patents
Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus Download PDFInfo
- Publication number
- WO1992001801A1 WO1992001801A1 PCT/FR1991/000588 FR9100588W WO9201801A1 WO 1992001801 A1 WO1992001801 A1 WO 1992001801A1 FR 9100588 W FR9100588 W FR 9100588W WO 9201801 A1 WO9201801 A1 WO 9201801A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- baculovirus
- promoter
- sequence
- gene
- polyhedrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to expression vectors obtained from modified baculoviruses, in which one of the two strong late promoters of wild baculovirus is inactive.
- Baculoviruses are currently used in a large number of laboratories as vectors for gene expression. Indeed, these viruses have the following advantages: they allow the insertion of long DNA segments and also have two strong late promoters, the polyhedrin promoter, and the P10 protein promoter, which are capable of inducing an extremely high level of expression of genes under their control.
- baculovirus AcNPV baculovirus Autographa californica
- NOV non-occlusive form
- OV occlusive form
- Non-occlusive forms are responsible for the transmission of the virus in cell culture or within the same organism.
- Occlusive forms are responsible for the transmission of the virus from one organism to another.
- These occlusive forms consist of virions wrapped in a crystalline protein matrix essentially consisting of a single protein: polyhedrin.
- the polyhedrin gene has been shown to have an exceptionally strong promoter that allows for a high level of expression of the gene under its control. MILLER therefore points out that it would be particularly advantageous to use baculoviruses as expression vectors, by inserting, under the control of the polyhedrin promoter, the exogenous DNA which it is desired to express.
- baculoviruses can contain large amounts of DNA and therefore does not constitute a limit to the number or length of the genes inserted. Consequently, very numerous expression vectors derived from baculoviruses have been proposed.
- European Patent Application 127,839 (SUMMERS invention) describes a process allowing the production of a recombinant expression vector, derived from baculovirus, by passing through a transfer vector containing a fragment of viral DNA which contains the promoter of the polyhedrin gene, downstream of which the foreign gene is inserted. This transfer vector is then recombined with the DNA of the wild baculovirus and the recombinants possessing the foreign gene under the control of the polyhedrin promoter are selected.
- European Patent Application 340 359 (Inventors PAGE and RODGERS) describes transfer vectors derived from baculoviruses, in which the initiation codon ATG for polyhedrin is deleted, so that the sequence coding for polyhedrin cannot be translated, and which carry a restriction site suitable for the insertion of an exogenous gene downstream of the N-terminal end of the polyhedrin gene, and in the immediate vicinity of said end.
- the team of inventors previously developed a process for the production of a modified baculovirus, usable as an expression vector, into which one inserts directly and without resorting to a vector of transfer, an appropriate restriction site, downstream of a strong late promoter.
- the vector thus obtained can be loaded, at the location of the restriction site introduced, with the gene which it is desired to express; this process is the subject of European Patent Application 345,152.
- the gene to be expressed is inserted under the control of one of the two strong late promoters present in the genome of the wild baculovirus, while the other promoter continues to function normally.
- the promoter of the P10 gene covers part of the sequence coding for the protein P26, and it is generally considered that a mutation in this promoter does not make it possible to obtain viable baculoviruses.
- the Inventors have discovered, unexpectedly, that the suppression or the inactivation of one of the two strong late promoters of the wild baculovirus had the consequence of increasing the expression of the gene placed under the control of the remaining promoter.
- the present invention aims to provide new expression vectors, constructed from modified baculoviruses, and in which only one of the two late promoters present in wild baculovirus is active.
- the present invention relates to expression vectors, characterized in that they are obtained from a modified baculovirus in which one of the two strong late promoters present in the genome of the wild baculovirus is inactive, and in that the sequence under the control of the highly active late promoter in said modified baculovirus is different from the corresponding sequence of wild baculovirus.
- sequence different from the corresponding sequence of wild baculovirus means in particular that the sequence which, in wild baculovirus, is controlled by the promoter considered, has undergone modifications aimed at allowing the expression of an exogenous gene under the control of said promoter.
- modifications include, for example, the insertion of an exogenous sequence (gene which it is desired to express, sequence carrying one or more restriction sites, etc.) in said sequence of wild baculovirus, or in place of all or part of it.
- the inactive promoter is that of the polyhedrin gene and the active promoter is that of the gene for the P10 protein.
- the inactive promoter is that of the P10 protein gene, and the active promoter is that of the polyhedrin gene.
- the invention also relates to modified baculoviruses usable for obtaining expression vectors as defined above.
- the invention includes modified, infectious baculoviruses, in which the promoter of the P10 protein gene is inactive.
- the gene for the P10 polypeptide which is located in the restriction fragment EcoRI P, is surrounded in 5 ′ by a gene coding for a polypeptide called P26, and in the 3 'region, by a gene coding for a polypeptide called P74.
- the promoter of the P10 gene is located at the 3 'end of the P26 gene, in the coding region of the latter.
- the inventors carried out the deletion of the region between an XhoI site (position +569 of the P26 gene) and a BglII site (position +152 of the P10 gene), then religated these sites, after repair by the enzyme of Klenow .
- the region corresponding to the promoter and to the 5 ′ end of P10 is thus deleted.
- a chimeric gene consisting of the first 569 bases of P26 and the last 130 bases of P10 is obtained; this gene is functional, and baculoviruses modified in this way are perfectly viable and produce more polyhedrin than the wild virus.
- the genome of said modified baculovirus is devoid of a DNA sequence comprised between the XhoI site located at + 569 bp from the ATG initiation codon of the sequence coding for the P26 polypeptide and the BglII site, located at + 152 bp from the ATG initiation codon of the sequence coding for the P10 polypeptide.
- the invention also encompasses the following baculoviruses, in which the promoter of the polyhedrin gene is inactive:
- a modified baculovirus whose genome is devoid of a DNA sequence between the EcoRV site located at -95 bp and the SspI site located +910 bp from the ATG initiation codon of the polyhedrin sequence.
- baculovirus whose genome is devoid of a DNA sequence between the EcoRV site located at -95 bp and the KpnI site located +633 bp from the ATG initiation codon of the polyhedrin sequence.
- baculovirus whose genome is devoid of a DNA sequence between the EcoRV site located at -95 bp and the Eco47III site located +733 bp from the ATG initiation codon of the sequence coding for polyedrine.
- the inventors have found that the baculoviruses thus modified multiply well in cell culture, and no longer produce the protein whose promoter is inactivated, but on the other hand, synthesize in greater quantity than the wild baculovirus, that in which the promoter is active.
- the modified baculoviruses contain a marker sequence, placed under the control of the active promoter.
- the term "marker sequence” means a sequence the expression of which confers on the modified baculovirus an easily identifiable phenotype.
- the subsequent insertion of an exogenous sequence inside said sequence results in the cancellation of said phenotype, which allows the selection of baculoviruses having integrated said exogenous sequence.
- the marker sequence consists of the sequence coding for polyhedrin, which sequence is placed under the control of the promoter of the P10 protein gene.
- the modified baculoviruses obtained in this way recover their capacity to produce inclusions.
- a baculovirus strain obtained in accordance with this provision was deposited, on July 17, 1990, with the National Collection of Microorganisms, held by the Pasteur Institute in Paris. This strain has the deposit number I-978.
- the modified baculovirus contains the sequence coding for ⁇ -galactosidase, placed under the control of the active promoter (P10 protein or polyhedrin). Baculoviruses modified in this way have the property of forming blue viral plaques in the presence of the X-gal substrate.
- baculoviruses obtained in accordance with one of the two preceding provisions makes it possible, during the subsequent insertion of a foreign gene, to easily select the recombinant viruses which have integrated said foreign gene inside the polyhedrin gene. or that of ⁇ -galactosidase.
- said recombinant viruses no longer form polyhedra; in the second case, they form white areas, instead of blue areas.
- modified baculoviruses usable for obtaining expression vectors in accordance with the invention, one proceeds to the inactivation, by any appropriate means, of one of the strong late promoters present in the genome of the wild baculovirus .
- the polyhedrin promoter or the promoter of the P10 protein is inactivated by excision of a DNA fragment comprising said promoter.
- the excision of said DNA fragment can be carried out using restriction enzymes.
- the inactivation of either of the two promoters can also be carried out by mutagenesis of sequences participating in the activity of said promoter, for example as described in the publication of RAKIN et al. cited above.
- Loaded expression vectors in accordance with the invention can be obtained from the modified baculoviruses, by various methods known per se, for example, and without limitation, using transfer vectors, such as those described in European Patent Applications 127,839 and 340,359, or by direct insertion, as described in European Patent Application 345,152).
- sequence coding for the exogenous protein which it is desired to express is inserted under the control of the active promoter; the sequence which, in wild baculovirus is normally placed under the control of said promoter, can be totally or partially excised, and replaced by the sequence encoding the exogenous protein.
- EXAMPLE 1 Construction of a modified baculovirus lacking the promoter and the polyhedrin structural gene
- Modified baculoviruses in accordance with the invention are obtained by partial digestion of the wild baculovirus DNA with two restriction enzymes, the cleavage sites of which are located for one of them, upstream of the polyhedrin promoter, and for the other, downstream of said promoter, either in the sequence coding for polyhedrin, or downstream of said sequence.
- the total genomic DNA of a baculovirus belonging to the Autographa californica strain is successively cut by the enzymes EcoRV and Eco47III according to the partial digestion technique described in "Current Protocols in Molecular Biology”; Ausubel et al. Eds. ; published by Geene Publishing Associates and Wiley Interscience (section 3.1.6.).
- 10 ⁇ g of Baculovirus DNA are diluted in 100 ⁇ l of 10 mM Tris HC1 buffer (pH 7.5), 10 mM MgCl2, 150 mM NaCl
- the dilution used is 1/27 for Eco RV. Switching off by Eco 47 III
- the experimental conditions are the same as those described for Eco RV.
- the dilution used is 1/54.
- the molecules cut by EcoRV and Eco47III are provided with blunt ends, which allows them to be directly ligated to obtain circular viral DNA molecules.
- the resulting viral DNA molecules are used, after purification, to transfect cultures of Spodoptera frugiperda cells (strain SF9, ATCC no CRL 1711), according to the protocol described by GRAHAM and VAN DER ERB, [Virology, 52, 305 - 309 (1973)].
- the DNA molecules carrying the desired deletion are infectious, and give viruses which produce plaques which do not form polyhedra.
- These viruses are called pob- viruses.
- the genomic DNA of the baculovirus Autographa Californica is digested successively with the enzymes KpnI and EcoRV, under the conditions described in Example I, except that the treatment with Kpn I is carried out in a buffer without NaCl, and at a dilution of 1/9.
- the molecules are then religated and used to transfect cultures of Spodoptera Frugiperda, as previously described.
- the procedure is as described in Examples 1 or 2, except that the wild baculovirus used belongs to the Galleria mellonella strain.
- the Eco R1-P restriction fragment obtained from the genome of the wild autographa Californica baculovirus, and which contains the P10 protein structural gene, is inserted into the multisite linker of the plasmid pUC9 at the Eco R1 site.
- This fragment contains a unique BglII site, located at +152 bp relative to the ATG codon of the P10 gene.
- a BamHI fragment comprising the major part of the ⁇ -galactosidase gene, (which has a BamHI site downstream of its own ATG) is inserted at the BglII site; the reading frames of the start of the P10 protein and of the ⁇ -galactosidase are thus in phase.
- the plasmid obtained therefore has the start of the P10 protein gene, and the ⁇ -galactosidase gene.
- Spodoptera frugiperda cells are cotransfected with the plasmid D3PZ and the DNA of the pob- virus (1 ⁇ g of D3PZ; 0.5 ⁇ g of pob- DNA; the protocol is identical to that of Example 1) and selects recombinant baculoviruses (pob- ⁇ -galactosidase), which form blue patches in the presence of X gal.
- the recombinant viruses obtained express the ⁇ -galactosidase in very large quantities, as shown in Example 7 below.
- EXAMPLE 5 Introduction of the polyhedrin structural gene in place of the P10 protein structural gene
- plasmid containing the Eco R1-P fragment of the genome of the baculovirus of Autographa californica (cf. example 4) is open at the BglII site.
- Klénow a BglII linker is introduced. This gives a plasmid called pGH 80-82, lacking the major part of the sequence coding for the protein P10, and carrying a BglII site in position -4 relative to the ATG of the protein P10.
- the polyhedrin structural gene excised from the plasmid pUC18 using the restriction enzymes PvuII and Eco47III, is introduced into the BglII site of the plasmid pGH 80-82, after restoration of the blunt ends with Klenow polymerase.
- the plasmid obtained called pGH 80-82 ob + is used, with the pob- virus obtained in Example 1, to cotransfect Spodoptera frugiperda cells.
- Recombinant viruses (pob-ob + ), which form polyhedra, are selected.
- a strain of recombinant virus (pob-ob + ) was deposited on July 17, 1990, with the National Collection of Microorganisms, under the number I-978.
- a cDNA fragment obtained from Ache mRNA was previously cloned into a plasmid pEMBL8 between the Sma I and Eco R1 sites. From said plasmid, the Ache gene is excised by the action of the enzymes FspI (site at -14 bp from the ATG codon of Ache) and SacI (site at + 117 bp from the termination codon of Ache).
- the fragment obtained is inserted into the plasmid pGH 80-22, at the Bgl II site, the ends of which were previously made blunt by the Klenow polymerase.
- the plasmid obtained is called pGH 80-22 Ache.
- This plasmid is used
- the recombinant viruses selected will be those which form white patches.
- EXAMPLE 7 Expression of the ⁇ -galactosidase gene: Comparison between recombinant baculoviruses known in the prior art and the expression vectors in accordance with the invention.
- the gene for ⁇ -galactosidase is "fused" to that of polyhedrin (Polyhedrin- ⁇ -Gal.).
- the recombinant virus is of the classical type (it has the two strong promoters);
- the recombinant virus is of the classic type (it has two strong promoters and makes polyhedra);
- the ⁇ -galactosidase gene has been fused to that of the P10 polypeptide (D3PZ).
- the recombinant virus, of the pob- type, no longer has the promoter or the polyhedrin gene.
- ⁇ -galactosidase activity is measured in the culture supernatant and in the cells themselves using ONPG as a chromogenic substrate. 3 measurements are made on each point.
- D3PZ cells contain 1.4 times more activity than Polyhedrin ⁇ -Gal cells. At 72 hours despite a cell lysis which becomes important, D3PZ still has more activity than the other constructions.
- EXAMPLE 8 Construction of a modified baculovirus lacking the promoter and the P10 protein structural gene
- the total genomic DNA of a baculovirus belonging to the Autographa californica strain is cut successively by the enzymes XhoI and BglII, according to the partial digestion technique indicated in Example 1.
- the conditions used are as follows: Cut by XhoI
- 10 ⁇ g of Baculovirus DNA are diluted in 100 ⁇ l of 50 mM Tris HCl buffer (pH 7.5), 10 mM MgCl 2 , 100 mM NaCl.
- the dilution used is, for XhoI, 1/27.
- 10 ⁇ g of Baculovirus DNA are diluted in 100 ⁇ l of 10 mM Tris HCl buffer (pH 7.5), 10 mM MgCl, 50 mM NaCl.
- the dilution used is 1/54.
- the resulting viral DNA molecules are used to transfect cultures of Spodoptera frugiperda cells.
- These viruses are called the P10- virus; they produce more polyhedrin than the wild virus.
- a Bam HI fragment of the gene for ⁇ -galactosidase (see Example 4) is inserted at the Bam HI site of said transfer vector.
- the vectors thus obtained are used, together with modified baculoviruses P10-, obtained by the protocol described in Example 8, to cotransfect the cells of Spodoptera frugiperda.
- the baculoviruses that have integrated the ⁇ -galactosidase gene no longer form polyhedra, but synthesize ⁇ -galactosidase, easily detectable and quantifiable by specific staining with the chromogenic substrate X-gal.
- the level of ⁇ -galactosidase produced 48 hours after infection is 25% higher in the modified baculoviruses lacking the promoter of the P10 protein than in the wild baculoviruses.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/966,197 US5571709A (en) | 1990-07-18 | 1991-07-17 | Modified baculovirus and baculovirus expression vectors |
CA002087270A CA2087270C (fr) | 1990-07-18 | 1991-07-17 | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus |
EP91913605A EP0651815B1 (fr) | 1990-07-18 | 1991-07-17 | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus |
DE69125632T DE69125632T2 (de) | 1990-07-18 | 1991-07-17 | Modifiziertes baculovirus, verfahren zu seiner herstellung, und dessen expressionsvektoren |
AU82324/91A AU660419B2 (en) | 1990-07-18 | 1991-07-17 | Modified baculovirus, method for obtaining it, and expression vectors obtained from said baculovirus |
NO93930145A NO930145L (no) | 1990-07-18 | 1993-01-15 | Modifisert baculovirus, fremgangsmaate ved fremstilling derav, og ekspresjonsvektorer erholdt fra denne baculovirus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR90/09143 | 1990-07-18 | ||
FR909009143A FR2664905B1 (fr) | 1990-07-18 | 1990-07-18 | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992001801A1 true WO1992001801A1 (fr) | 1992-02-06 |
Family
ID=9398840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1991/000588 WO1992001801A1 (fr) | 1990-07-18 | 1991-07-17 | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus |
Country Status (14)
Country | Link |
---|---|
US (1) | US5571709A (fr) |
EP (1) | EP0651815B1 (fr) |
JP (1) | JP3076833B2 (fr) |
AT (1) | ATE151462T1 (fr) |
AU (1) | AU660419B2 (fr) |
CA (1) | CA2087270C (fr) |
DE (1) | DE69125632T2 (fr) |
FR (1) | FR2664905B1 (fr) |
HU (1) | HUT62937A (fr) |
IE (1) | IE912525A1 (fr) |
NO (1) | NO930145L (fr) |
NZ (1) | NZ239032A (fr) |
PT (1) | PT98357B (fr) |
WO (1) | WO1992001801A1 (fr) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400382B (de) * | 1994-06-24 | 1995-12-27 | Inject Star Poekelmasch | Vorrichtung zum quetschen und auflockern von fleisch |
WO1996029400A1 (fr) * | 1995-03-23 | 1996-09-26 | Institut National De La Recherche Agronomique (Inra) | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en ×uvre dudit procede |
WO2006069246A2 (fr) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides |
WO2008030558A2 (fr) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations |
WO2009067636A2 (fr) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Polypeptides d'insuline modifiés et leurs utilisations |
WO2010011735A2 (fr) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Polypeptides g-csf bovins modifiés et leurs utilisations |
WO2010037062A1 (fr) | 2008-09-26 | 2010-04-01 | Ambrx, Inc. | Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels |
US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
EP2284191A2 (fr) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Procédé de préparation de hGH |
US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
EP2327724A2 (fr) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Polypeptides d'hormone de croissance humaine et leur utilisations |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2012024452A2 (fr) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Polypeptides de relaxine modifiés et leurs utilisations |
US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
EP2805964A1 (fr) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Polypeptides modifiés de somatotrophine bovine et leurs utilisations |
EP2805965A1 (fr) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Polypeptides modifiés de somatotrophine bovine et leurs utilisations |
US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP3103880A1 (fr) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Polypeptides d'insuline modifiés et utilisations de ceux-ci |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
US11993637B2 (en) | 2021-02-02 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003040297A (ja) * | 2001-08-06 | 2003-02-13 | Toppan Printing Co Ltd | オーバーキャップ付封緘キャップ |
EP2292271A3 (fr) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelage et glycoconjugation des anticorps |
ZA200700168B (en) | 2001-10-10 | 2010-02-24 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
CA2569381A1 (fr) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle |
CN102703446B (zh) * | 2005-08-18 | 2014-05-28 | Ambrx公司 | tRNA组合物和其用途 |
NZ567234A (en) * | 2005-11-08 | 2011-09-30 | Ambrx Inc | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
CA2631491C (fr) * | 2005-12-14 | 2015-02-24 | Ambrx, Inc. | Compositions contenant des acides amines et polypeptides non naturels, procedes mettant en jeu ceux-ci et utilisations de ceux-ci |
EP2413962A1 (fr) | 2009-03-30 | 2012-02-08 | Mount Sinai School of Medicine | Vaccins pour le virus influenza et leurs utilisations |
JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
WO2010144794A1 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins polypeptidiques de fusion exprimés par baculovirus avec immunogénicité accrue et leurs utilisations |
WO2010144797A2 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations |
CA2790380A1 (fr) | 2010-02-18 | 2011-08-25 | Mount Sinai School Of Medicine | Vaccins destines a etre utilises pour la prophylaxie et le traitement d'une maladie liee au virus de la grippe |
CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
EP2579892A2 (fr) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable |
KR20140146993A (ko) | 2011-05-11 | 2014-12-29 | 칠드런'즈 메디컬 센터 코포레이션 | 다항원 제시 면역성 조성물, 및 그 방법 및 용도 |
CA2842392C (fr) * | 2011-07-27 | 2020-09-15 | Genethon | Systemes d'expression de baculovirus perfectionnes |
CN104185476A (zh) | 2011-09-20 | 2014-12-03 | 西奈山医学院 | 流感病毒疫苗及其应用 |
CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
CA2899659C (fr) | 2013-01-28 | 2023-09-05 | Kansas State University Research Foundation | Glycoproteines gn et gc du virus de la fievre de la vallee du rift, et leur utilisation |
US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
WO2016118937A1 (fr) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Régimes de vaccination contre le virus de la grippe |
CN109641041A (zh) | 2016-06-15 | 2019-04-16 | 西奈山伊坎医学院 | 流感病毒血细胞凝集素蛋白及其用途 |
CA3058652A1 (fr) | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations |
AT519931A1 (de) * | 2017-05-12 | 2018-11-15 | Kepler Univ Gmbh | Herstellung von armierter DNA |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0127839A2 (fr) * | 1983-05-27 | 1984-12-12 | THE TEXAS A&M UNIVERSITY SYSTEM | Procédé pour la préparation d'un vecteur recombinant d'expression de baculovirus |
-
1990
- 1990-07-18 FR FR909009143A patent/FR2664905B1/fr not_active Expired - Fee Related
-
1991
- 1991-07-17 EP EP91913605A patent/EP0651815B1/fr not_active Expired - Lifetime
- 1991-07-17 DE DE69125632T patent/DE69125632T2/de not_active Expired - Fee Related
- 1991-07-17 AU AU82324/91A patent/AU660419B2/en not_active Ceased
- 1991-07-17 HU HU93118A patent/HUT62937A/hu unknown
- 1991-07-17 WO PCT/FR1991/000588 patent/WO1992001801A1/fr active IP Right Grant
- 1991-07-17 PT PT98357A patent/PT98357B/pt not_active IP Right Cessation
- 1991-07-17 AT AT91913605T patent/ATE151462T1/de not_active IP Right Cessation
- 1991-07-17 JP JP03512351A patent/JP3076833B2/ja not_active Expired - Fee Related
- 1991-07-17 CA CA002087270A patent/CA2087270C/fr not_active Expired - Fee Related
- 1991-07-17 US US07/966,197 patent/US5571709A/en not_active Expired - Fee Related
- 1991-07-18 IE IE252591A patent/IE912525A1/en unknown
- 1991-07-18 NZ NZ239032A patent/NZ239032A/xx unknown
-
1993
- 1993-01-15 NO NO93930145A patent/NO930145L/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0127839A2 (fr) * | 1983-05-27 | 1984-12-12 | THE TEXAS A&M UNIVERSITY SYSTEM | Procédé pour la préparation d'un vecteur recombinant d'expression de baculovirus |
Non-Patent Citations (6)
Title |
---|
Biological Abstracts Database, abrégé no. 88037377, J. Qin et al.: "Studies on the control region of the P10 gene of the Autographa-californica nuclear polyhedrosis virus", & J. Gen. Virology, 1989, vol. 70, no. 5, p. 1273-1280, voir l'abrégé (cité dans la demande) * |
Biotechnology Abstracts Database, abrégé no. 88-01644, R.D. Possee et al.: "Analysis of the polyhedrin gene promoter of the Autographa californica nuclear polyhedrosis virus. Potential baculo virus vector for foreign gene expression", & Nucleic Acids Res. 1987, vol. 15, no. 24, p. 10233-48, voir l'abrégé * |
Gene, volume 70, no. 1, 15 octobre 1988, Elsevier Science Publishers B.V. (Amsterdam, NL) C. Rankin et al.: "Eight base pairs encompassing the transcriptional start point are the major determinant for baculovirus polyhedrin gene expression", pages 39-49, voir le document en entier (cité dans la demande) * |
Gene, volume 75, no. 1, 30 janvier 1989, Elsevier Science Publishers B.V. (Amsterdam, NL) K. Iatrou et al.: "Bombyx mori nuclear polyhedrosis virus-based vectors for expressing passenger genes in silkmoth cells under viral or cellular promoter control", pages 59-71, voir l'article en entier (cité dans la demande) * |
Journal of General Virology, volume 69, no. 4, avril 1988 (Colchester, GB) J.M. Vlak et al.: "Functional studies on the p10 gene of Autographa californica nuclear polyhedrosis virus using a recombinant expressing a p10-beta-galactosidase fusion gene", pages 765-776, voir l'article en entier * |
Journal of General Virology, volume 71, no. 7, juillet 1990, (Colchester, GB) U. Weyer et al.: "Analysis of very late gene expression by Autographa californica nuclear polyhedrosis virus and the further development of multiple expression vectors", pages 1525-1534, voir l'article en entier * |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT400382B (de) * | 1994-06-24 | 1995-12-27 | Inject Star Poekelmasch | Vorrichtung zum quetschen und auflockern von fleisch |
WO1996029400A1 (fr) * | 1995-03-23 | 1996-09-26 | Institut National De La Recherche Agronomique (Inra) | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en ×uvre dudit procede |
FR2732035A1 (fr) * | 1995-03-23 | 1996-09-27 | Agronomique Inst Nat Rech | Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede |
EP2327724A2 (fr) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Polypeptides d'hormone de croissance humaine et leur utilisations |
US9260472B2 (en) | 2004-02-02 | 2016-02-16 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8906676B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8907064B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8232371B2 (en) | 2004-02-02 | 2012-07-31 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
US8097702B2 (en) | 2004-02-02 | 2012-01-17 | Ambrx, Inc. | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses |
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
EP2399893A2 (fr) | 2004-12-22 | 2011-12-28 | Ambrx, Inc. | Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations |
US7838265B2 (en) | 2004-12-22 | 2010-11-23 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7846689B2 (en) | 2004-12-22 | 2010-12-07 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7858344B2 (en) | 2004-12-22 | 2010-12-28 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7883866B2 (en) | 2004-12-22 | 2011-02-08 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
EP2284191A2 (fr) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Procédé de préparation de hGH |
US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
US7939496B2 (en) | 2004-12-22 | 2011-05-10 | Ambrx, Inc. | Modified human growth horomone polypeptides and their uses |
US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
US7829310B2 (en) | 2004-12-22 | 2010-11-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7959926B2 (en) | 2004-12-22 | 2011-06-14 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone mutants |
US8178494B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Modified human growth hormone formulations with an increased serum half-life |
US8178108B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
US8163695B2 (en) | 2004-12-22 | 2012-04-24 | Ambrx | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
WO2006069246A2 (fr) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions contenant des acides amines non naturels et des polypeptides, procedes impliquant ces acides amines non naturels et polypeptides, et utilisations desdits acides amines non naturels et polypeptides |
US8143216B2 (en) | 2004-12-22 | 2012-03-27 | Ambrx, Inc. | Modified human growth hormone |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
WO2008030558A2 (fr) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
US8053560B2 (en) | 2006-09-08 | 2011-11-08 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US8022186B2 (en) | 2006-09-08 | 2011-09-20 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
US7919591B2 (en) | 2006-09-08 | 2011-04-05 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US8618257B2 (en) | 2006-09-08 | 2013-12-31 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2009067636A2 (fr) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Polypeptides d'insuline modifiés et leurs utilisations |
US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
EP2930182A1 (fr) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Polypeptides d'insuline modifiés et utilisations de ceux-ci |
EP3103880A1 (fr) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Polypeptides d'insuline modifiés et utilisations de ceux-ci |
US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
EP3225248A1 (fr) | 2008-07-23 | 2017-10-04 | Ambrx, Inc. | Polypeptides g-csf bovins modifiés et leurs utilisations |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
WO2010011735A2 (fr) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Polypeptides g-csf bovins modifiés et leurs utilisations |
US9121025B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US10428333B2 (en) | 2008-09-26 | 2019-10-01 | Ambrx Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
WO2010037062A1 (fr) | 2008-09-26 | 2010-04-01 | Ambrx, Inc. | Vaccins et micro-organismes dépendant de la réplication d'acide aminé non naturels |
US9156899B2 (en) | 2008-09-26 | 2015-10-13 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
US9644014B2 (en) | 2008-09-26 | 2017-05-09 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
EP3216800A1 (fr) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Polypeptides d'érythropoïétine animale modifiés et leurs utilisations |
US8569233B2 (en) | 2008-09-26 | 2013-10-29 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
EP2805965A1 (fr) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Polypeptides modifiés de somatotrophine bovine et leurs utilisations |
EP2805964A1 (fr) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Polypeptides modifiés de somatotrophine bovine et leurs utilisations |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US11311605B2 (en) | 2010-08-17 | 2022-04-26 | Ambrx, Inc. | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides |
WO2012024452A2 (fr) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Polypeptides de relaxine modifiés et leurs utilisations |
EP4302783A2 (fr) | 2010-08-17 | 2024-01-10 | Ambrx, Inc. | Polypeptides de relaxine modifiés et leurs utilisations |
US11786578B2 (en) | 2010-08-17 | 2023-10-17 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US11439710B2 (en) | 2010-08-17 | 2022-09-13 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
US8735539B2 (en) | 2010-08-17 | 2014-05-27 | Ambrx, Inc. | Relaxin polypeptides comprising non-naturally encoded amino acids |
US9452222B2 (en) | 2010-08-17 | 2016-09-27 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
US10702588B2 (en) | 2010-08-17 | 2020-07-07 | Ambrx, Inc. | Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain |
US10751391B2 (en) | 2010-08-17 | 2020-08-25 | Ambrx, Inc. | Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11993637B2 (en) | 2021-02-02 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
Also Published As
Publication number | Publication date |
---|---|
NO930145D0 (no) | 1993-01-15 |
JP3076833B2 (ja) | 2000-08-14 |
DE69125632D1 (de) | 1997-05-15 |
FR2664905B1 (fr) | 1994-08-12 |
AU660419B2 (en) | 1995-06-29 |
NZ239032A (en) | 1993-10-26 |
HUT62937A (en) | 1993-06-28 |
ATE151462T1 (de) | 1997-04-15 |
FR2664905A1 (fr) | 1992-01-24 |
EP0651815B1 (fr) | 1997-04-09 |
DE69125632T2 (de) | 1997-10-23 |
CA2087270A1 (fr) | 1992-01-19 |
JPH06500010A (ja) | 1994-01-06 |
NO930145L (no) | 1993-03-15 |
AU8232491A (en) | 1992-02-18 |
EP0651815A1 (fr) | 1995-05-10 |
PT98357A (pt) | 1992-05-29 |
CA2087270C (fr) | 2001-12-04 |
HU9300118D0 (en) | 1993-04-28 |
IE912525A1 (en) | 1992-01-29 |
PT98357B (pt) | 1999-01-29 |
US5571709A (en) | 1996-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0651815B1 (fr) | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus | |
EP0345152B1 (fr) | Baculovirus modifié, son procédé de préparation et son application en tant que vecteur d'expression de gènes | |
Bettstetter et al. | AFV1, a novel virus infecting hyperthermophilic archaea of the genus Acidianus | |
EP0314569B1 (fr) | Virus du fowlpox recombinant, vecteurs d'expression de protéines héterologues et vaccins pour la volaille dérivés de ce virus | |
EP0870046B1 (fr) | Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline | |
Costes et al. | Cloning of the koi herpesvirus genome as an infectious bacterial artificial chromosome demonstrates that disruption of the thymidine kinase locus induces partial attenuation in Cyprinus carpio koi | |
FR2573436A1 (fr) | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins | |
FR2705686A1 (fr) | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. | |
JPH11506612A (ja) | Aav特異的標的化組込み | |
AU4665389A (en) | Position-specific insertion vectors and method of using same | |
SK42295A3 (en) | Purificated and isolated dna molecule, analogue of beta-subunit of tryptophansynthetasy, tryptophansynthetasy, prokaryotic or eukaryotic host cell, method of biosynthesis of indole and indigo | |
JPH04500312A (ja) | 自己アセンブルド欠損非自己増殖性ウイルス粒子 | |
FR2604183A1 (fr) | Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho | |
WO2001098453A2 (fr) | Vecteurs d'expression comprenant un fragment modifie de l'operon tryptophane | |
Strauss et al. | Efficient oligodeoxyribonucleotide-directed deletion mutagenesis using pEMBL vectors: removal of early region introns from polyoma virus mutants | |
EP2424878B1 (fr) | Modification du genome d'un bacteriophage lytique par immobilisation dudit bacteriophage dans sa bacterie hote | |
FR2656531A1 (fr) | Promoteur artificiel pour l'expression de proteines dans le levure. | |
JPH01157393A (ja) | 酵母における安定なゲノム組込みおよび外来コーディング配列の発現 | |
KR101223577B1 (ko) | 재조합바이러스 비이지박 (bEasyBac)과 이를 이용한 베큘로바이러스 발현벡터계 | |
FR2743818A1 (fr) | Constructions d'adn et vecteurs d'expression derives du gene de l'arn va i d'adenovirus | |
EP2205747A1 (fr) | Souches e. coli attenuees invasives et leurs applications comme vecteur intracellulaire de molecule therapeutique | |
That | Cloning of the Koi Herpesvirus Genome as | |
FR2659350A1 (fr) | Sequences nucleotidiques issues de l'arn genomique du virus de la septicemie hemorragique virale, applications a la synthese ou a la detection d'acides nucleiques, produits d'expression de ces sequences et application desdits produits a la prevention et au diiagnostic de la septicemie hemorragique virale. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BG CA CS FI HU JP NO PL SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991913605 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2087270 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2108014 Country of ref document: CA Kind code of ref document: A Ref document number: 2108014 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991913605 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991913605 Country of ref document: EP |